EN DE
Watch Rua Life Sciences PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rua Life Sciences PLC (RUA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Rua Life Sciences PLC stock £0.26, price £0.26, upside +2.0%, quality 45 out of 100. Rating: fairly valued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare GB · ISIN GB0033360586

RL Rua Life Sciences PLC logo Thin data Nov 4, 2026

Rua Life Sciences PLC

RUA · LSE
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value £0.2600 · Fairly valued
Quality 45/100
Mixed Growth (revenue 5y +23.9 %/yr in GBP)
Thin margins · 6.1% net margin (TTM)
Negative free cash flow
Trails peers (2/11)
Narrow moat 22/100 · thin data
Thin data
Watch Rua Life Sciences PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

£1.65 £0.0875 Fair Value £0.2600 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range £0.0875 – £1.65 · fair‑value band £0.1500 – £0.4600 · the £0.2550 price screens below the £0.2600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Rua Life Sciences in your weekly email

Every Wednesday you see whether Rua Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

RUA Life Sciences plc, together with its subsidiaries, develops medical devices in Europe, North America, the Middle East, the Asia Pacific, and Africa. It operates through four segments: Biomaterials, Contract Manufacture, Vascular, and Structural Heart.

Show moreShow less

The company acts as the depository of intellectual property and licensing rights to various biostable and implantable polymers, including Elast-Eon and ECSil; and provides sub-contract manufacturing, assembly, packing, and services of medical device, as well as implantable fabric.

It also engages in the development and commercialization of bore polymer sealed grafts and soft tissue patches; and development of tri-leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020.

RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.

Stock analysis

Rua Life Sciences PLC (RUA) currently trades at £0.2550, while our model-based Fair Value estimate is £0.2600, so the stock looks roughly fairly valued today (gap 1.9%).

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: £0.1500 (bear) to £0.4600 (bull), the price of £0.2550 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Rua Life Sciences PLC reported revenue of £4.5M in FY2026 versus £1.6M in FY2022, a compound +28.7%/yr. Reported net income was −£145K in FY2026.

Key figures

Market cap £15.8M Micro · P/S ratio 3.63 · Net margin −3.3% · Return on equity 0.0% · Return on assets (EBIT) −26.5% (4-year average) · Operating margin −8.5% · Revenue (TTM) £4.6M · Revenue growth (YoY) +6.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 15% below its 52-week high and 113% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 2%, RUA screens cheaper than that median.

Fair Value models

Bear £0.1500 Fair Value £0.2600 Bull £0.4600
Price £0.2550 · Upside +2.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings £0.1500 £0.2600 £0.4600 74
NCAV (Graham) £0.0400 £0.0600 £0.0700 55
All 2 models by family
DCF Models
Owner Earnings £0.1500 £0.2600 £0.4600 74
Asset-Based
NCAV (Graham) £0.0400 £0.0600 £0.0700 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 24
Are margins and returns getting better?
Cashflow 12
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 83
Does it invest with discipline instead of growing at any price?
Low Volatility 41
How calm the share price moves, does not count
Price momentum 64
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 88
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+23.9%
Start year 2021 (pandemic). Over 10 years: +21.7% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−117.5% (2021) → −18.5% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch RUA, get fair value alerts →

Compare Rua Life Sciences PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks

Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside +2.0% · Above median
Profitability
Return on equity (12 months) 0.0% · Below median
Return on assets −1.6% · Below median
Net margin (12 months) 6.1% · Below median
Operating margin (12 months) −8.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 6.1% · Below median
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.17× · Pricier than median
P/S (12 months) 3.43× · Pricier than median
EV/EBITDA 21.6× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)36 · sector 6
FUTURE (revenue growth)31 · sector 36
PAST (return on equity)0 · sector 17
HEALTH (low debt)99 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs RUA
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs RUA
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥202.57 +10% vs RUA
DexCom, Inc DXCM $79.41 $87.35 +10% vs RUA
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs RUA
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs RUA
Siemens Healthineers AG SHL €44.66 €34.51 −23% vs RUA
Abbott Laboratories, ABT $109.93 $75.28 −32% vs RUA
Medtronic plc MDT $101.80 $65.61 −36% vs RUA
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs RUA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rua Life Sciences PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rua Life Sciences PLC Fair Value". https://www.fairvalue-calculator.com/stock/RUA

Frequently asked questions

Is Rua Life Sciences PLC (RUA) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of £0.2600 versus a price of £0.2550, about +2% upside (fairly valued).
What is the fair value of RUA?
Our model-based fair value for Rua Life Sciences PLC is £0.2600 (as of Nov 4, 2026), built from audited fundamentals. The current price: £0.2550.
What is the quality score of RUA?
Rua Life Sciences PLC has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rua Life Sciences PLC (RUA)?
Our model-based price target is the fair value of £0.2600 (as of Nov 4, 2026) from 2 valuation models. Cautious scenario £0.1500, optimistic scenario £0.4600. It is a calculation from audited fundamentals, not an analyst target.
What is the Rua Life Sciences PLC stock forecast for 2026?
Our models put fair value at £0.2600, about +2% upside versus a price of £0.2550 (fairly valued). Cautious scenario £0.1500, optimistic scenario £0.4600. The calculation is refreshed regularly with new filings.
What is the revenue of Rua Life Sciences PLC (RUA)?
Rua Life Sciences PLC reported trailing-twelve-month revenue of about £4.6M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Rua Life Sciences PLC (RUA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rua Life Sciences PLC it is £0.2600 per share (as of Nov 4, 2026), against a price of £0.2550. It is the blended result of 2 valuation models in 2 families (DCF Models, Asset-Based).
Is Rua Life Sciences PLC stock overvalued or undervalued in 2026?
As of Nov 4, 2026, RUA trades below its calculated fair value: price £0.2550, fair value £0.2600, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RUA?
No. The price is what the market pays today (£0.2550); the fair value is what the company's own numbers justify (£0.2600). For Rua Life Sciences PLC the two are £0.0050 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rua Life Sciences PLC worth?
The market values Rua Life Sciences PLC at about £15.8M (market capitalisation, as of Nov 4, 2026). Per share that is £0.2550; our models calculate a fair value of £0.2600 per share.
What do the bullish and bearish scenarios say about RUA?
Our models span a range for Rua Life Sciences PLC: cautious scenario £0.1500, base £0.2600, optimistic £0.4600 per share (as of Nov 4, 2026, price £0.2550). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rua Life Sciences PLC (RUA)?
Balance-sheet figures for Rua Life Sciences PLC (as of Nov 4, 2026): return on equity 0.0%, debt of 0.02 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is RUA from its 52-week high?
Rua Life Sciences PLC trades at £0.2550, about 15% below its 52-week high of £0.3000 and 113% above the low of £0.1200 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £0.2600 is for.
Which stocks are comparable to Rua Life Sciences PLC?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rua Life Sciences PLC stock attractive at the current price?
The data as of Nov 4, 2026: price £0.2550, calculated fair value £0.2600 (+2%), Quality Score 45/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RUA calculated?
We run Rua Life Sciences PLC through 2 models from 2 families: DCF Models, Asset-Based. Every model gets the same audited fundamentals; the fair value of £0.2600 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Rua Life Sciences PLC currently trades 2% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rua Life Sciences PLC (RUA)?
The closing price on Nov 6, 2026 was £0.2550. Our model-based fair value is £0.2600, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rua Life Sciences PLC right now?
The model range is unusually wide (£0.1500 to £0.4600). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Rua Life Sciences PLC

How large is the market capitalisation of Rua Life Sciences PLC (RUA)?
The market capitalisation of Rua Life Sciences PLC is £15.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rua Life Sciences PLC (RUA)?
The price-to-sales ratio of Rua Life Sciences PLC is 3.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Rua Life Sciences PLC (RUA)?
The net margin of Rua Life Sciences PLC is −3.3% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rua Life Sciences PLC (RUA)?
The return on equity (ROE) of Rua Life Sciences PLC is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rua Life Sciences PLC (RUA)?
On an EBIT basis the return on assets of Rua Life Sciences PLC is −26.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rua Life Sciences PLC (RUA)?
The operating margin of Rua Life Sciences PLC is −8.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rua Life Sciences PLC (RUA)?
Revenue at Rua Life Sciences PLC is growing +6.1% versus a year earlier (3y avg +27.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rua Life Sciences PLC (RUA) generate?
The free cash flow of Rua Life Sciences PLC is −£298K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Rua Life Sciences PLC (RUA) hold?
Rua Life Sciences PLC holds more cash than debt, £2.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Rua Life Sciences PLC in the live analysis

One click puts Rua Life Sciences PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.